This TIGIT targeting approach will have two benefits - one on tumor cells and the other on cytotoxic immune cells - allowing CD226 to bind to CD155 to reactivate T cells and NK cells for anti-tumor cytotoxic killing. This evidence concerns the gene PVR and neoplasm.